Differential regulation of the human κ opioid receptor by agonists: Etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 531-540

  Li, Jian Guo ^a   Zhang, Fengqin ^a   Jin, Xi Lu ^a   Liu Chen, Lee Yuan ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ADENYLATE CYCLASE; DYNORPHIN A; EPITOPE; ETORPHINE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LEVORPHANOL; NALOXONE; NORBINALTORPHIMINE; SULFUR 35;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; STAINING;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ADENYLATE CYCLASE; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CYCLIC AMP; DYNORPHINS; ETORPHINE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FORSKOLIN; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LEVORPHANOL; PHOSPHORYLATION; RECEPTORS, OPIOID, KAPPA;

EID: 0037405881     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045559     Document Type: Article

References (48)

1. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, von Zastrow M, Grandy DK, and Williams JT (2002) mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization and internalization. J Neurosci 22:5769-5776.
2. Appleyard SM, Celver J, Pineda V, Kovoor A, Wayman GA, and Chavkin C (1999) Agonist-dependent desensitization of the kappa opioid receptor by G protein receptor kinase and beta-arrestin. J Biol Chem 274:23802-23807.
3. Appleyard SM, Patterson TA, Jin WZ, and Chavkin C (1997) Agonist-induced phosphorylation of the kappa-opioid receptor. J Neurochem 69:2405-2412.
4. Arden JR, Segredo V, Wang Z, Lameh J, and Sadee W (1995) Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 65:1636-1645.
5. Avidor-Reiss T, Zippel R, Levy R, Saya D, Ezra V, Barg J, Matus-Leibovitch N, and Vogel Z (1995) Kappa-opioid receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opioid treatments. FEBS Lett 361:70-74.
6. Bhargava HN, Gulati A, and Ramarao P (1989) Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. J Pharmacol Exp Ther 251:21-26.
7. Blake AD, Bot G, Freeman JC, and Reisine T (1997a) Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 272:782-790.
8. Blake AD, Bot G, Li SX, Freeman JC, and Reisine T (1997b) Differential agonist regulation of the human kappa-opioid receptor. J Neurochem 68:1846-1852.
9. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, and Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature (Lond) 408:720-723.
10. Bot G, Blake AD, Li SX, and Reisine T (1997) Opioid regulation of the mouse delta-opioid receptor expressed in human embryonic kidney 293 cells. Mol Pharmacol 52:272-281.
11. Chang K-J (1984) Opioid receptors: multiplicity and sequelae of ligand-receptor interactions, in The Receptors (Conn PM ed) vol 1, pp 1-81, Academic Press, Inc., New York.
12. Chen C, Xue JC, Zhu J, Chen YW, Kunapuli S, Kim de Riel J, Yu L, and Liu-Chen L-Y (1995) Characterization of irreversible binding of beta-funaltrexamine to the cloned rat mu opioid receptor. J Biol Chem 270:17866 -17870.
13. Chu P, Murray S, Lissin D, and von Zastrow M (1997) Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. J Biol Chem 272:27124-27130.
14. Dykstra LA, Gmerek DE, Winger G, and Woods JH (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413-420.
15. Finn AK and Whistler JL (2001) Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal (See comments). Neuron 32:829-839.
16. Gage RM, Kim KA, Cao TT, and von Zastrow M (2001) A transplantable sorting signal that is sufficient to mediate rapid recycling of G protein-coupled receptors. J Biol Chem 276:44712-44720.
17. He L, Fong J, von Zastrow M, and Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271-282.
18. Huang P, Kehner GB, Cowan A, and Liu-Chen L-Y (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
19. Jordan BA, Cvejic S, and Devi LA (2000) Kappa opioid receptor endocytosis by dynorphin peptides. DNA Cell Biol 19:19-27.
20. Jordan BA and Devi LA (1999) G-Protein-coupled receptor heterodimerization modulates receptor function. Nature (Lond) 399:697-700.
21. Joseph DB and Bidlack JM (1995) The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line down-regulates without desensitizing during chronic opioid exposure. J Pharmacol Exp Ther 272:970-976.
22. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Manteillet-Agius G, Stewart PL, Evans CJ, and von Zastrow M (1998) mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53:377-384.
23. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
24. Kieffer BL (1995) Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides (Review). Cell Mol Neurobiol 15:615-635.
25. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, and Yamamura HI (1995) Molecular biology and pharmacology of cloned opioid receptors (Review). FASEB J. 9:516-525.
26. Law P-Y, Wong YH, and Loh HH (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389-430.
27. Li J, Li JG, Chen C, Zhang F, and Liu-Chen L-Y (2002) Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl] benzeneacetamide-induced desensitization and phosphorylatian phosphorylation between human and rat κ-opioid receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 61:73-84.
28. Li JG, Benovic JL, and Liu-Chen L-Y (2000) Mechanisms of agonist-induced downregulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol 58:795-801.
29. Li JG, Luo LY, Krupnick JG, Benovic JL, and Liu-Chen L-Y (1999) U50,488Hinduced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. J Biol Chem 274:12087-12094.
30. Ling K, Ma L, and Pei G (1998) Differential efficacies of kappa agonists to induce homologous desensitization of human kappa opioid receptor. Neurosci Lett 240:25-28.
31. Mansour A, Khachaturian H, Lewis ME, Akil H, and Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308-314.
32. Mhaouty-Kodja S, Barak LS, Scheer A, Abuin L, Diviani D, Caron MG, and Cotecchia S (1999) Constitutively active alpha-lb adrenergic receptor mutants display different phosphorylation and internalization features. Mol Pharmacol 55:339-347.
33. Morris BJ and Herz A (1989) Control of opiate receptor number in vivo: simultaneous κ-receptor down-regulation and μreceptor up-regulation following chronic agonist/antagonist treatment. Neuroscience 29:433-442.
34. Murray C and Cowan A (1988) Neuroadaptation of rats to kappa agonists U-50,488 and tifluadom. Natl Inst Drug Abuse Res Monogr 81:136-142.
35. Pfeiffer A, Brantl V, Herz A, and Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science (Wash DC) 233:774-776.
36. Pierce KL, Premont RT, and Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639-650.
37. Pippig S, Andexinger S, and Lohse MJ (1995) Sequestration and recycling of β2-adrenergic receptors permit receptor resensitization. Mol Pharmacol 47:666-676.
38. Scaramellini C and Leff P (1998) A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type, Ann NY Acad Sci 861:97-103.
39. Schulz R, Wehmeyer A, and Schulz K (2002) Visualizing preference of G proteincoupled receptor kinase 3 for the process of kappa-opioid receptor sequestration. Mol Pharmacol 61:1444-1452.
40. Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, von Zastrow M, Evans C, and Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246.
41. Tallent M, Dichter MA, and Reisine T (1998) Differential regulation of the cloned kappa and mu opioid receptors. Neuroscience 85:873-885.
42. Tsao P, Cao T, and von Zastrow M (2001) Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 22:91-96.
43. von Voigtlander PF, Lahti RA, and Ludens JH (1983) U-50, 488: a selective and structurally novel non-μ (κ) opioid agonist, J Pharmacol Exp Ther 224:7-12.
44. Xue J-C, Chen C, Zhu J, Kunapuli S, de Riel JK, Yu L, and Liu-Chen L-Y (1994) Differential binding domains of peptide and nonpeptide ligands in the rat κ opioid receptor: a chimeric receptor study. J Biol Chem 269:30195-30199.
45. Zhang F, Li J, Li JG, and Liu-Chen L-Y (2002) (-)U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(I-pyrrolidinyl)-cyclohexyl] benzeneacetamide] induces internalization and down-regulation of the human, but not the rat, kappa-opioid receptor: structural basis for the differential regulation. J Pharmacol Exp Ther 302:1184-1192.
46. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law P-Y, and Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162.
47. 35S]GTPγS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676-684.
48. Zhu J, Luo LY, Mao GF, Ashby B, and Liu-Chen L-Y (1998) Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in CHO cells. J Pharmacol Exp Ther 285:28-36.